Producer
Hangzhou Motto Science & Technology Co., Ltd.
Leading Asia-Pacific PVP manufacturer; ~18% of global PVP market in 2024 per Spherical Insights.
1
Inputs supplied
1
Goods downstream
0
Facilities
0
Stories
What they make
1 input Hangzhou Motto Science & Technology Co., Ltd. supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Hangzhou Motto Science & Technology Co., Ltd. makes, pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
Pharmaceutical-Grade PVP (Povidone/Crospovidone)
60%Industrial & Personal Care PVP
25%NVP Monomer & Pyrrolidone Chemistry
15%
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Did you know2018
PVP (polyvinylpyrrolidone) is copolymerized directly into the silicone hydrogel polymer matrix of modern premium contact lenses — not applied as a surface coating, but chemically incorporated as a wetting comonomer that migrates to the lens surface during wear to maintain moisture. Alcon's DAILIES Total1 lens (the world's leading premium daily contact lens) uses a water-gradient material where PVP creates a ~100% water surface layer. The PVP that Hangzhou Motto produces for pharmaceutical tablet binding is chemically identical to the PVP that must be incorporated into contact lens manufacturing — requiring pharma-grade purity. A Chinese PVP supply disruption would simultaneously affect generic tablet manufacturing (pharmaceutical supply) and the contact lens manufacturing supply chain that determines whether premium daily contact lenses can be produced at current volumes.
Journal of Functional Biomaterials ↗Concentration2024
China produces approximately 50-60% of the world's polyvinylpyrrolidone (PVP) supply, concentrated in Zhejiang and Henan provinces. Hangzhou Motto (Zhejiang) and Boai NKY (Henan) together account for approximately 35-40% of global PVP output. Together with BASF's Kollidon brand (Germany), these three companies control the majority of global pharmaceutical-grade PVP supply. PVP is a non-substitutable tablet binder in thousands of generic drug formulations — switching to an alternative binder requires pharmaceutical reformulation and regulatory re-submission, a process taking 18-36 months per drug product. The entire global pharmaceutical tablet manufacturing industry's binder supply chain depends on Chinese producers and a single German company. In 2020, the COVID-19 pandemic disrupted Chinese chemical production and triggered the first significant PVP pharmaceutical supply shortage events in decades, briefly revealing this concentration to the pharma industry.
Spherical Insights ↗